Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA filing plans.
STOK - Stoke Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$43.86
DETAILS
HIGH:
$60.00
LOW:
$35.00
MEDIAN:
$40.00
CONSENSUS:
$43.86
UPSIDE:
49.49%
Stock News
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on May 15, 2026, it granted stock options to purchase an aggregate of 106,200 shares of common stock to eight n.
Stoke Therapeutics Q1 Earnings Call Highlights
Stoke Therapeutics NASDAQ: STOK said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year open-label extension data, while the company remains on track to complete enrollment in its pivotal Phase 3 EMPEROR study in June.
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to earnings of $1.9 per share a year ago.
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the first quarter ended March 31, 2026, and announced new 4-year longitudinal d.
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome
I initiate Stoke Therapeutics with a Buy rating, driven by late-stage progress for zorevunersen in SCN1A Dravet Syndrome. STOK's phase 3 EMPEROR trial for zorevunersen targets mid-2027 data and a rolling NDA submission in the first half of 2027. Three-year open-label data show durable seizure reduction and functional improvement, supporting disease-modifying potential for zorevunersen.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on April 15, 2026, it granted stock options to purchase an aggregate of 129,565 shares of common stock to fourt.
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, Ap.
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. “Clare brings more than three decades of industry experience,.
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
The chair of Stoke Therapeutics disclosed selling 4,355 shares for roughly $174,000 at around $40.00 per share on March 10, 2026. The sale represented 12.20% of Tzianabos' direct Common Stock holdings, reducing direct ownership to 31,339 shares.
Assenagon Asset Management S.A. Boosts Position in Stoke Therapeutics, Inc. $STOK
Assenagon Asset Management S.A. boosted its holdings in Stoke Therapeutics, Inc. (NASDAQ: STOK) by 36.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,227,723 shares of the company's stock after purchasing an additional 327,451 shares during the quarter. Assenagon Asset Management
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally
The chief medical officer of Stoke Therapeutics disposed of 14,311 Common Stock shares for a transaction value of $457,000 across three days ending March 19, 2026. This sale represented 26.01% of Ticho's direct common stockholdings before the transaction, reducing direct ownership from 55,013 to 40,702 shares.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on March 16, 2026, it granted stock options to purchase an aggregate of 58,650 shares of common stock to six ne.
Stoke Therapeutics (NASDAQ:STOK) Trading Down 6.6% After Insider Selling
Stoke Therapeutics, Inc. (NASDAQ: STOK - Get Free Report)'s share price was down 6.6% during mid-day trading on Friday following insider selling activity. The stock traded as low as $34.69 and last traded at $34.0860. Approximately 130,341 shares changed hands during trading, a decline of 82% from the average daily volume of 720,330 shares. The stock
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New England Journal of Medicine (NEJM). The publication includes results from two completed Phase 1/2a and ongoing open-label extension (OLE) studies.
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3,.
45,205 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Principal Financial Group Inc.
Principal Financial Group Inc. bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 45,205 shares of the company's stock, valued at approximately $1,062,000. Principal Financial Group Inc. owned approximately
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on February 17, 2026, it granted stock options to purchase an aggregate of 22,950 shares of common stock to fiv.
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that the first patient has been dosed in the Phase 1 OSPREY study of STK-002, an investigational medicine for the treatment of Autosomal Dominant Optic Atrophy (ADOA). ADOA is a rare genetic disease that causes progressive and irreversible vision loss in both eyes starting in the first de.
Price Targets
Stoke Therapeutics initiated with an Outperform at Wolfe Research
$40.00
(was $36.23)
Wolfe Research
Stoke Therapeutics initiated with a Buy at Guggenheim
$60.00
(was $32.00)
Yatin Suneja
·
Guggenheim
Stoke Therapeutics price target raised to $36 from $32 at Wedbush
$36.00
(was $28.14)
Wedbush
Stoke Therapeutics price target raised to $36 from $28 at Canaccord
$36.00
(was $30.90)
Canaccord Genuity
Chardan Capital Markets Assumes Stoke Therapeutics (STOK) at Buy
$35.00
(was $30.90)
Keay Nakae
·
Loop Capital Markets
Stoke Therapeutics (STOK) PT Raised to $50 at H.C. Wainwright
$50.00
(was $32.90)
Andrew Fein
·
H.C. Wainwright
Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright
$50.00
(was $32.82)
UBS
Stoke Therapeutics price target raised to $28 from $24 at Canaccord
$28.00
(was $21.42)
Canaccord Genuity
Stoke Therapeutics price target raised to $35 from $22 at Needham
$35.00
(was $29.90)
Needham
Stoke Therapeutics price target lowered to $28 from $29 at BTIG
$28.00
(was $18.10)
Thomas Shrader
·
BTIG
Stoke Therapeutics assumed with an Outperform at Leerink
$18.00
(was $11.84)
Marc Goodman
·
Leerink Partners
H.C. Wainwright Reiterates Buy Rating on Stoke Therapeutics (STOK)
$35.00
(was $15.32)
Debjit Chattopadhyay
·
H.C. Wainwright
Stoke Therapeutics (STOK) PT Lowered to $20 at Canaccord Genuity
$20.00
(was $11.87)
Sumant Kulkami
·
Canaccord Genuity
Stoke Therapeutics (STOK) PT Raised to $22 at Needham, latest STK-001 'data put STOK in a strong position heading into regulatory discussions'
$22.00
(was $6.50)
Joseph Stringer
·
Needham
Stoke Therapeutics (STOK) PT Raised to $21 at Canaccord Genuity
$21.00
(was $10.92)
Sumant Kulkami
·
Canaccord Genuity
Needham Maintains Buy on Stoke Therapeutics, Lowers Price Target to $25
$25.00
(was $9.33)
Needham
Stoke Therapeutics assumed with an Outperform at Credit Suisse
$58.00
(was $32.50)
Judah Frommer
·
Credit Suisse